A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer
Keywords: پمترکسید، آلیمتا; Non-small-cell lung cancer; Cost comparison; First-line maintenance; Erlotinib; Pemetrexed; Lung cancer;